NASDAQ:RYM

RYTHM Q1 2026 Earnings Results & Report

RYTHM logo
$11.83 +0.60 (+5.34%)
Closing price 04:00 PM Eastern
Extended Trading
$12.24 +0.40 (+3.42%)
As of 05:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

RYTHM reported Q1 2026 earnings on May 5, 2026. The company reported EPS of $1.33, while revenue was $13.29 million.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes

RYTHM EPS Results

Actual EPS
$1.33
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

RYTHM Revenue Results

Actual Revenue
$13.29 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

RYTHM Q1 2026 Earnings FAQ

RYTHM (NASDAQ:RYM) reported earnings of $1.33 per share for Q1 2026. The report was announced on Tuesday, May 5, 2026.

RYTHM reported revenue of $13.29 million for Q1 2026.

RYTHM Earnings Headlines

RYTHM, Inc. Reports Third Quarter 2026 Results
ELON + YOU + DECEMBER 8TH
Elon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.tc pixel
RYTHM Inc
See More RYTHM Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like RYTHM? Sign up for Earnings360's daily newsletter to receive timely earnings updates on RYTHM and other key companies, straight to your email.

About RYTHM

I couldn’t verify a Nasdaq-listed company named RYTHM (NASDAQ:RYM) with the ticker RYM. If you mean Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM), it is a biopharmaceutical company developing treatments for rare genetic diseases and other conditions linked to the brain’s melanocortin-4 receptor pathway, which helps regulate hunger and body weight.

Its marketed medicine, Imcivree (setmelanotide), is approved in the United States for certain forms of rare genetic obesity and acquired hypothalamic obesity. The company is based in Boston and focuses on developing and providing therapies for patients in the United States and other markets.

View RYTHM Profile